stockrowAktis Oncology, Inc. (AKTS) vs Rigel Pharmaceuticals, Inc. (RIGL)
- Aktis Oncology, Inc. AKTS 15.78 +6.26%
- Rigel Pharmaceuticals, Inc. RIGL 39.59 −13.39%
Aktis Oncology, Inc. and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. Aktis Oncology, Inc. and Rigel Pharmaceuticals, Inc. are of similar size ($853.9M and $826.0M). Aktis Oncology, Inc. has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.4×. Rigel Pharmaceuticals, Inc. has the higher net margin (106.6% vs −782.0%) and the higher return on invested capital (13.7% vs 0.00%). Across the 15 metrics below, Rigel Pharmaceuticals, Inc. leads on 13 and Aktis Oncology, Inc. on 2.
Valuation
Profitability
| Metric | AKTS | RIGL | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 89.64% | 68.51% |
| Operating margin | (939.13%) | 26.28% | 0.00% |
| Net margin | (781.95%) | 106.59% | 0.00% |
| Free cash flow margin | (1,442.91%) | 31.20% | 0.00% |
| Return on equity | (34.45%) | 109.18% | (51.96%) |
| Return on assets | (22.22%) | 80.16% | (46.06%) |
| Return on invested capital | 0.00% | 13.69% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack